Antiplatelet treatment in the primary prophylaxis of cardiovascular disease in patients with arterial hypertension

Abstract

The benefits of using acetylsalicylic acid (ASA) in the primary prophylaxis of cardiovascular diseases may only slightly exceed the risk of serious bleeding. This warrants the search for alternative, safer preparations with antiaggregatory properties, which could be used in patients burdened with cardiovascular risk factors. Antiaggregatory compounds identified in water-soluble tomato extract include nucleosides, flavonoids, and phenolic acids. The action of standardized tomato extract is multidirectional, reversible, and weaker in comparison to ASA. The European Food Safety Authority (EFSA) has approved this preparation as a dietary agent with antiaggregatory properties. The use of standardized tomato extract appears beneficial in arterial hypertension patients with low or moderate cardiovascular risk and in patients in whom good pressure control cannot be achieved.

Favourable hypotensive effect after standardised tomato extract treatment in hypertensive subjects at high cardiovascular risk: a randomised controlled trial

“…The role of ASA in primary prevention of CV diseases has been consistently reduced, mainly because of the risk of serious bleeding [5,9]. The aim of the current study was to examine whether STE could be an alternative safe and anti-aggregatory agent that could be used instead of ASA in individuals with high CV risk.…”

“…They are a source of bioactive compounds of anti-oxidative action such as L-ascorbic acid, polyphenols, isoflavonoids, and carotenoids (lycopene, beta-carotene) [5][6][7][8]. The consumption of tomatoes can potentially reduce or delay the development of CV disease by anti-aggregation, antihypertensive, antidiabetic, antioxidative, antiangiogenic, and protective endothelial effects [5,7]. In a previous study, the authors investigated the anti-aggregation effect of the standardised tomato extract (STE) in hypertensive patients with high CV risk.…”